Annual report pursuant to Section 13 and 15(d)

Agreements (Details)

Agreements (Details) (USD $)	12 Months Ended			1 Months Ended									36 Months Ended	108 Months Ended
Agreements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2009	May 31, 2013	Aug. 31, 2013	Sep. 30, 2013	Jan. 31, 2002	Apr. 30, 2008	Jul. 31, 2014	Dec. 31, 2011	Jul. 31, 2012	Dec. 31, 2004	Dec. 31, 2014
Agreements [Line Items]
Research and development	$ 16,779,589us-gaap_ResearchAndDevelopmentExpense	$ 23,710,183us-gaap_ResearchAndDevelopmentExpense	$ 16,890,482us-gaap_ResearchAndDevelopmentExpense
Common Stock, shares issued	150,200,259us-gaap_CommonStockSharesIssued	135,919,423us-gaap_CommonStockSharesIssued												150,200,259us-gaap_CommonStockSharesIssued
Reliable Supply Agreement [Member]
Agreements [Line Items]
Purchases under manufacture and supply agreement	300,000	666,000	939,000
Purchase orders issued	0													0
Initial term				10 years
Resolution term				60 days
Nordion Supply Agreement [Member]
Agreements [Line Items]
Purchases under manufacture and supply agreement	505,000	771,000
Purchase orders issued	317,000													317,000
Initial term					3 years
Resolution term					30 days
Notice period					180 days
PETNET Supply Agreement [Member]
Agreements [Line Items]
Purchases under manufacture and supply agreement	2,200,000	1,400,000
Purchase orders issued	132,000													132,000
Initial term						3 years
Resolution term						30 days
Notice period						60 days
Automatic renewal date						1 year
OsoBio Supply Agreement [Member]
Agreements [Line Items]
Purchases under manufacture and supply agreement	96,000	1,200,000
Purchase orders issued	463,000													463,000
Resolution term							60 days
Notice period							12 months
Automatic renewal date							2 years
Lymphoseek License Agreement [Member]
Agreements [Line Items]
License fee								25,000
License maintenance fee								25,000
Minimum annual royalty								25,000
Research and development	353,000	273,000	33,000
Lymphoseek Expanded License Agreement [Member]
Agreements [Line Items]
License fee									25,000
License maintenance fee									25,000
Minimum annual royalty									25,000
Research and development	25,000	29,000	31,000
Tilmanocept License Agreement [Member] [Domain]
Agreements [Line Items]
License fee										25,000
License maintenance fee										25,000
Minimum annual royalty										25,000
Research and development	25,000
Astra Zeneca Agreement [Member]
Agreements [Line Items]
Research and development	81,000	5,000	14,000
Astra Zeneca Agreement [Member] \| Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
Agreements [Line Items]
License fee											5,000,000.0
Contingent milestone payment											6,500,000.0
Astra Zeneca Agreement [Member] \| Milestone Payments Based On Receipt Of Certain Regulatory Approvals And Initiation Of Commercial Sales Of Licensed Product [Member]
Agreements [Line Items]
Contingent milestone payment											11,000,000.0
Alseres Pharmaceuticals Inc [Member]
Agreements [Line Items]
Research and development	42,000	366,000	1,800,000
Contingent milestone payment												2,900,000.0
Sublicense execution payment, cash paid												175,000
Common Stock, shares issued												300,000
Alseres Pharmaceuticals Inc [Member] \| Alseres Milestone Payments Based On Product Registration Or Commercial Sales [Member]
Agreements [Line Items]
Contingent milestone payment												2,500,000.0
Common Stock, shares issued												950,000
Alseres Pharmaceuticals Inc [Member] \| Milestone Payments Maximum [Member]
Agreements [Line Items]
Common Stock, shares issued												1,150,000.00
Cardiosonix [Member]
Agreements [Line Items]
Grants received from Office of the Chief Scientist													775,000
Royalty expense														84,000
Accrued royalties	0													0
Cardiosonix [Member] \| Minimum [Member]
Agreements [Line Items]
Royalty on net sales of licensed products , percentage	3.00%
Cardiosonix [Member] \| Maximum [Member]
Agreements [Line Items]
Royalty on net sales of licensed products , percentage	5.00%
Royalty percentage on grant revenues	300.00%
Employment Agreement [Member]
Agreements [Line Items]
Maximum contingent liability	$ 2,900,000													$ 2,900,000
Employment Agreement [Member] \| Minimum [Member]
Agreements [Line Items]
Ratio of entitled salary	1.2													1.2
Employment Agreement [Member] \| Maximum [Member]
Agreements [Line Items]
Ratio of entitled salary	2.0													2.0